Diabetes Impacts Mortality in Breast Cancer Patients

Share this content:
Diabetes Impacts Mortality in Breast Cancer Patients
Diabetes Impacts Mortality in Breast Cancer Patients

FRIDAY, Jan. 26, 2018 (HealthDay News) -- Breast cancer-specific mortality remains higher among women with diabetes who have longer diabetes duration or preexisting cardiovascular disease, according to a study published online Jan. 19 in Diabetes Care.

Iliana C. Lega, M.D., from the University of Toronto, and colleagues used Ontario administrative databases to compare the rate of receipt of breast cancer treatments between women with and without diabetes.

The researchers found that women with diabetes and stage III breast cancer were slightly less likely to receive chemotherapy (relative risk [RR], 0.93; 95 percent confidence interval [CI], 0.89 to 0.97), although this difference was not significant when adjusting for comorbidities (adjusted hazard ratio [aHR], 1.03; 95 percent CI, 0.93 to 1.13). Similar results were seen for receipt of guideline-adherent radiotherapy (RR, 0.97; 95 percent CI, 0.95 to 0.99; aHR, 0.98; 95 percent CI, 0.94 to 1.02). After adjusting for comorbidities, all-cause mortality was higher in women with diabetes (aHR, 1.16; 95 percent CI, 1.06 to 1.27), but, overall, there was no increase in breast cancer-specific mortality. However, among women with a longer duration of diabetes or preexisting cardiovascular disease there was increased all-cause and cancer-specific mortality.

"Although cancer treatments received were similar between women with and without diabetes, breast cancer-specific mortality remains higher among women with diabetes who have longer diabetes duration or preexisting cardiovascular disease," the authors write. "This study uncovers new information about key risk factors for poorer prognosis in women with diabetes and breast cancer."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths